安凱客車(000868.SZ):與JMS公司簽署約4.36億元的銷售合同
格隆匯1月18日丨安凱客車(000868.SZ)公佈,公司作為賣方,近日與JMS公司(“買方”,限於保密義務,不披露其全稱)簽署了《SALES CONTRACT》(《銷售合同》),合同金額6880萬美元(約合人民幣4.36億元);合同的履行期限:2022年6月前分批交付。
公司與買方共同參與了墨西哥某市政公交800台招標項目併成功中標。買方已與市政府簽訂了銷售合同並收到了政府的預付款。其具有良好的發展能力,履約能力較強。
該合同金額約佔公司2020年度經審計的營業收入的13.37%。預計該合同將對公司2022年度銷售收入和利潤總額產生積極的影響,有利於公司業績的提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.